12:00 PM EDT, 03/13/2026 (MT Newswires) -- GSK (GSK) said Friday the US Food and Drug Administration expanded the approved age indication of Arexvy to adults aged 18 to 49 at heightened risk of lower respiratory tract disease from the respiratory syncytial virus.
The FDA's decision was supported by data from phase 3 trials.
The company said it will keep advancing regulatory submissions for its RSV vaccine across geographies to increase access and support growth objectives.
Price: 53.85, Change: -0.43, Percent Change: -0.79